Skip to main content

Cabtreo FDA Approval History

FDA Approved: Yes (First approved October 20, 2023)
Brand name: Cabtreo
Generic name: adapalene, benzoyl peroxide and clindamycin phosphate
Dosage form: Topical Gel
Company: Bausch Health Companies Inc.
Treatment for: Acne

Last updated by Judith Stewart, BPharm on Oct 30, 2023.

Cabtreo (adapalene, benzoyl peroxide and clindamycin phosphate) is a triple-combination for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older.

Development timeline for Cabtreo

DateArticle
Oct 20, 2023Approval FDA Approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.